Overlap time is an independent risk factor of radiation pneumonitis for patients treated with simultaneous EGFR-TKI and thoracic radiotherapy

Comparisons between the National Comprehensive Cancer Network (NCCN) non-small-cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009

Yan Xu, Hongyu Liu, Jun Chen et al. · Thoracic Cancer · 2010 · 890 citations

Chinese Version, Advanced Lung Disease, Medicine +14

ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial

Malcolm Ranson, Lisa A. Hammond, D. K. Ferry et al. · Journal of Clinical Oncology · 2002 · 762 citations

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

Yuankai Shi, Li Zhang, Xiaoqing Liu et al. · The Lancet Oncology · 2013 · 420 citations

Double-blind Phase 3, Medicine, Metronomic Therapy +9

Mechanisms of Enhanced Radiation Response following Epidermal Growth Factor Receptor Signaling Inhibition by Erlotinib (Tarceva)

Prakash Chinnaiyan, Shyhmin Huang, Geetha D. Vallabhaneni et al. · Cancer Research · 2005 · 384 citations · Full text

Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer

Kayoko Tsujino, Saeko Hirota, Masahiro Endo et al. · International Journal of Radiation Oncology*Biology*Physics · 2002 · 357 citations

Nuclear Medicine, Medical Imaging, Dose-volume Histogram Parameters +11